National Statement on Ethical Conduct in Human Research – 2023: Comprehensive Study Notes

National Statement on Ethical Conduct in Human Research – 2023: Comprehensive Study Notes

THE NATIONAL STATEMENT: A USER GUIDE AND CONTEXT

• Purpose: promotes ethically good human research; clarifies responsibilities of institutions, researchers, and review bodies; supports accountability and governance alongside the Australian Code for the Responsible Conduct of Research.
• Structure overview:
  • Section 1: Values and principles of ethical conduct.
  • Section 2: Themes in research ethics—risk and benefit, consent (including consent modalities and waivers).
  • Section 3: Ethical considerations in design, development, review, and conduct of research (seven core elements; biospecimens, genomics, xenotransplantation chapters).
  • Section 4: Ethical considerations specific to participants (pregnant women/fetus; children and young people; dependent/unequal relationships; those highly dependent on medical care; cognitive impairment/mental illness; illegal activities; Aboriginal and Torres Strait Islander Peoples; research in other countries).
  • Section 5: Research governance and ethics review (institutional governance, responsibilities of HRECs, researchers, monitoring, conflicts of interest, complaints, accountability).
• Scope: applies to all human research funded by or conducted under NHMRC, ARC, UA; provides national standards for researchers, institutions, governments, industry, and other organisations.
• Foundational ethics: situates in historical context (Nuremberg Code, Helsinki Declaration, international human rights instruments) and emphasises public trust and the altruistic contribution of participants.
• Core legal context: recognises Australian common law, statutory obligations, and consistency with international rights instruments; does not exhaust ethical discussion—supplements with field-specific guidelines when aligned.

PREAMBLE AND PURPOSE

• Ethical background: human research involves ethical questions about trust, consent, autonomy, protection for those with diminished capacity, and community interests.
• Public responsibility: research with public interactions carries a duty to be ethically acceptable to the Australian community; governance includes institutions’ responsibilities for quality, safety, and ethics.
• Relationship between governance and guidelines: the National Statement sits with the Australian Code; both promote responsible, accountable conduct.
• Authors: NHMRC, ARC, UA; statutory basis and authority for issuing guidelines.

PURPOSE, SCOPE AND LIMITS OF THIS DOCUMENT

• Purpose: foster ethically good human research and protect participants; clarify responsibilities for design, review, conduct, and dissemination.
• Who should use it: researchers, review bodies (HRECs and others), governance actors, potential participants.
• Definition of research: broad but not exhaustively defined; emphasizes relevance to society and the need for ethical review proportional to risk.
• Human research: broad participation scope, including data and tissue, and recognition that research may affect nonparticipants and broader communities.
• When is ethical review needed: institutions establish review procedures; risk-based review levels (HREC for greater than low risk; lower-risk review pathways described); exemptions possible in certain contexts.
• Legal alignment: focuses on ethical design and review; governance and statutory responsibilities exist outside the National Statement.

SECTION 1: VALUES AND PRINCIPLES OF ETHICAL CONDUCT

• Core values: respect for human beings, research merit and integrity, justice, beneficence.
• Respect as central: includes safeguarding autonomy, protecting those with diminished capacity, and empowering participants.
• Other guiding values: altruism, cultural diversity, and Aboriginal and Torres Strait Islander ethical guidelines.
• Principles expressed in 1.1–1.13:
  • 1.1–1.3: Research merit and integrity (design, expertise, dissemination).
  • 1.4–1.5: Justice (fair recruitment, burden-benefit distribution, non-exploitation).
  • 1.6–1.9: Beneficence (minimise harms, justify risks, suspend if risks outweigh benefits).
  • 1.10–1.12: Privacy, confidentiality, cultural sensitivity; respect for privacy and community agreements.
  • 1.13: For diminished capacity, empower and protect as needed.
• Application and context: ethical deliberation should be ongoing; use in conjunction with field-specific guidelines when consistent.

SECTION 2: THEMES IN RESEARCH ETHICS: RISK AND BENEFIT, CONSENT

• Two overarching themes always considered:

  • Risks and benefits of the research; justification of risk by potential benefit; minimisation/mitigation strategies.
  • Consent: voluntary, informed, and based on understanding.

• Chapter 2.1: Risk and benefit

  • Risk definition: potential for harm or discomfort; involves likelihood and severity/magnitude of harm; can affect participants, groups, or nonparticipants.
  • Risk continuum and risk profiling (Figure 1): lower risk, minimal risk, low risk, greater than low risk, high risk; decisions on ethics review tied to risk level and safeguards.
  • Harms to consider: physical, psychological, devaluation, cultural harm, social harm, economic, legal harms; discomfort is lighter but can become harm if it escalates.
  • Burden and inconvenience: not harm, but burdens to participants; should be weighed against benefits.
  • Assessment of risk: identify/assess risks, justify benefits, minimise risks, consult evidence, consider data-linking data and large data sets with best-practice frameworks.
  • Benefit-risk balancing: higher risk requires greater justification and monitoring; informed by evidence; consider participant willingness to assume risk when appropriate.
  • Guidelines 2.1.1–2.1.5: procedure for identifying risks, benefits, mitigation, beneficiaries, and justification; use external expertise when needed.

• Chapter 2.2: General requirements for consent

  • Consent is a voluntary choice with sufficient information and understanding (2.2.1).
  • Adequate understanding includes purpose, methods, demands, risks, and benefits; information delivered in participant-suitable formats (2.2.3).
  • Consent process should enable mutual understanding with opportunity for questions (2.2.4).
  • Modes of consent: oral, written, or other means depending on research nature and participant context (2.2.5).
  • Information to be disclosed (2.2.6): alternatives, monitoring, services for adverse effects, contact details, privacy protections, withdrawal rights, funding, conflicts of interest, payments, dissemination plans, potential community benefits, and other necessary specifics.
  • Identity considerations: design so that voluntary decision to participate is clearly established (2.2.7).
  • Re-consent: renegotiation/confirmation in long or complex studies or with vulnerable participants (2.2.8).
  • Coercion and pressure: no undue coercion; consent must be voluntary (2.2.9).
  • Reimbursement: reasonable cost coverage; avoid coercive incentives (2.2.10–2.2.11).
  • Capacity considerations and involvement of others in decision-making (2.2.12–2.2.13).
  • Consent for future use of data/tissue: specific/extended/unspecified consent; complexity of future use (2.2.14–2.2.18).
  • Consent withdrawal and data access: withdrawal rights; data/data withdrawal implications (2.2.19–2.2.20).

• Chapter 2.3: Qualifying or waiving conditions for consent

  • Limited disclosure spectrum; opt-out and waiver concepts; regulatory alignment with privacy law (s95; s95A) where applicable (2.3.1–2.3.4).
  • Opt-out approach: appropriate only in limited-risk, high-public-interest contexts; requires safeguards (2.3.5–2.3.7).
  • Waiver of consent: HREC may waive consent only when risks are low, benefits justify non-consent, impracticability of obtaining consent, privacy protections in place, and plan to share benefits if applicable (2.3.9–2.3.12).
  • Waiver reporting: institutions should publicly describe consent waivers after project completion (2.3.12).
  • Guidance for addressing illegal activity: special considerations and approvals for waivers regarding exposure of illegal activity (2.3.11).

• Section 3: Ethical considerations in the design, development, review and conduct of research

  • Aims: guidance on ethical issues across research stages; four principles from Section 1 inform design and oversight.
  • Fourteen Elements of Chapter 3.1: Element 1–7 cover the full lifecycle from scope to after the project; Chapters 3.2, 3.3, 3.4 provide topic-specific guidance.
  • Biospecimens, genomics, xenotransplantation require dedicated chapters.
  • Distinction between research and innovative clinical practice; in some cases, advice from HREC is needed for new interventions.
  • Aboriginal and Torres Strait Islander research guidance emphasizes meaningful engagement and reciprocity; consult AIATSIS guidelines and NHMRC consumer/community participation guidelines.

• Element 1: Research Scope, Aims, Themes, Questions and Methods (3.1.1–3.1.9)

  • Researchers must clearly articulate: research question(s), potential benefits and beneficiaries, literature basis or prior research, how design/ methods achieve aims, respect for participants, compliance with regulations, review history/outcomes.
  • Merit and integrity criteria: relevance to field, data quality, generalisability, and appropriate expertise.
  • Designs may be informed by participant experience; flexibility in innovative/qualitative research; plan for safety and resources.
  • Interventional health research considerations: assess therapeutic benefit, compare to standard care, justify risks against potential benefits; ensure benefits do not overstate potential advantages.
  • Registration of prospective interventional health trials in a public register prior to recruitment (ICTRP/WHS standard) (3.1.7).
  • When designing stage-wise or adaptive trials, provide foreseen stages and ethics-approval plan (3.1.8).
  • Resource and facility assurances; ensure no undue influence from payments; provide infrastructure for long-term monitoring where needed (3.1.9, 3.1.10, 3.1.11).

• Element 2: Recruitment (3.1.12–3.1.21)

  • Recruitment strategies must align with justice and respect; include inclusion/exclusion criteria, potential coercion risks, relationship effects, and consent facilitation.
  • Provide recruitment materials in advance; consider multiple recruitment strategies for multi-cohort studies (3.1.19–3.1.20).
  • Consider impact of recruitment on consent, including potential pressure from researchers or relationships; disclosures about payments to recruiters.

• Element 3: Consent (3.1.21–3.1.35)

  • Tailor consent strategies to project and participants; multiple strategies may be needed for multi-method/multi-group studies (3.1.23).
  • Written information is not always required; consent can be implied by conduct where appropriate (3.1.24).
  • Ensure information is concise, proportionate to risk, and consider staged/tiered information (3.1.25).
  • Clarify who will know who was approached, who participated, and who provided consent (3.1.26).
  • Consider masking participant identity if significant risks arise from status disclosure (3.1.27).
  • If recruiters are paid, disclose to potential participants (3.1.28).
  • Explain services that could be impacted by participation and clarify withdrawal implications (3.1.29).

• Element 4: Collection, Use and Management of Data and Information (3.1.32–3.1.41)

  • Define data vs information; identifiability and re-identification risks; data linkage concerns.
  • Develop a data management plan addressing security, storage, access, sharing, disposal, and participant communication (3.1.44).
  • Data sharing and databank considerations; duties of custodians; consent for future use (extended/unspecified) (3.1.45–3.1.49).
  • Secondary use of data: risks of identifiability; publicly available data contexts (3.1.49–3.1.53).
  • Publication/privacy considerations in disseminating data; plan for de-identification and minimising identifiability in publications (3.1.41, 3.1.60–3.1.61).

• Element 5: Communication of Research Findings or Results to Participants (3.1.61–3.1.66)

  • Consider return of individual vs. overall findings; plan for clinical relevance and counselling needs; ensure appropriate expertise for interpretation and disclosure (3.1.63–3.1.66).

• Element 6: Dissemination of Outputs and Outcomes (3.1.67–3.1.71)

  • Public availability of findings aligns with merit and public good; lay summaries for participants; adherence to ethical reporting standards; timetable considerations for dissemination.

• Element 7: After the Project (3.1.71–3.1.73)

  • Retention, storage, and disposal of data; potential for long-term significance; intellectual property and copyright considerations; continuation of monitoring or follow-up if required.

SECTION 3: ETHICAL CONSIDERATIONS IN SPECIFIC TOPICS

• Chapter 3.2: Human Biospecimens in Laboratory-Based Research
  • Biospecimens include tissue, blood, urine, etc., and derivatives (cell lines); governance must address collection, storage, distribution, disposal, and potential employee/relatives implications.
  • Prospective biospecimen collection requires HREC ethics review; considerations for risks to donors/relatives/community if information could be derived.
  • Use of stored biospecimens may be lower-risk; 3.2.3–3.2.5 discuss review levels for low-risk stored samples.
  • Recruitment sources include voluntary donation, clinical material, post-mortem material (3.2.4–3.2.5).
  • Use of biospecimens from clinical care: waivers of consent may apply if identity is not needed; otherwise, consent processes apply (3.2.6, 3.2.12).
  • Import/export considerations and transition provisions for existing biospecimens (3.2.7–3.2.10).
  • Communicating with donors about return of information from biospecimens (3.2.15).
  • Provisions for information that may be health-relevant to donors/relatives and how to manage and/or disclose (3.2.15–3.2.22).
  • Guidelines for data/use of biospecimens including sharing with other researchers and international transfers (3.2.7–3.2.9).
• Chapter 3.3: Genomic Research
  • Genomic data have hereditary and familial implications; relatives may be affected; governance must address familial communication and consent.
  • Genomic research generally requires HREC review; may be lower risk if data are non-identifiable and no data linkage planned (3.3.3).
  • Recruitment considerations: include relatives by association; initial contact often should be with the participant rather than researchers (3.3.4–3.3.9).
  • Consent specifics: what information is generated, what will be disclosed, health implications for participant/relatives, potential re-identification risks, sharing with other groups, and future use (3.3.10–3.3.14).
  • Opt-out approach is not appropriate for genomic research (3.3.15).
  • Returning findings: three-category framework (must return; may be returned; should not be returned); process for verification, clinical validity, counselling, and responsibility for disclosure (3.3.26–3.3.33).
  • Generating and handling incidental/secondary findings; need for ethically defensible return plans; limitations on responsibilities to re-analyze findings over time (3.3.34–3.3.35).
  • Biobank role in return of findings is not generally assumed; explicit policies required (3.3.42).
  • Guidelines for validation, clinical utility, and personnel with genetics expertise to assist with interpretation and counselling (3.3.45–3.3.57).
  • Privacy and identifiability risks in genomic data, including potential re-identification and data storage needs for future analysis (3.3.58–3.3.61).
• Chapter 3.4: Animal-to-Human Xenotransplantation
  • Xenotransplantation involves live cells/tissues/organs from animals; requires specialized risk assessment due to xenozoonosis and long-term monitoring.
  • Ethical review via HREC; consider public interest, risks to participants and close contacts, and safety monitoring over long durations (3.4.1–3.4.7).
  • Risk management plan must address xenozoonoses, long-term monitoring, data privacy, and transfer of responsibility for monitoring/care (3.4.5).
  • Definitions of “close contacts” and long-term monitoring requirements; consent considerations for long-term follow-up (3.4.2–3.4.7).
  • Ethical justification requires balancing potential benefits against unknown or long-term risks; monitoring and safety infrastructure must be adequate (3.4.3–3.4.5).

SECTION 4: ETHICAL CONSIDERATIONS SPECIFIC TO PARTICIPANTS

• Chapter 4.1: Women who are pregnant and the human fetus
  • Wellbeing of the woman and fetus takes precedence; information separate from routine clinical care; consent considerations with potential involvement of others; separation of research and routine care unless therapeutic innovative therapy.
  • Minimise fetal pain/distress; counselling access; ensure no trade in fetal tissue; fetus or fetal tissue consent processes separated from termination decisions.
  • Termination decisions should not be influenced by recruitment for research; post-termination fetal tissue use requires consent and separation from clinical decisions; counselling available (4.1.1–4.1.23).
• Chapter 4.2: Children and young people
  • Capacity varies with maturity; levels of consent depend on age and understanding; consent by child or parent depending on maturity and risk; standing parental consent for school settings under certain conditions; best interests standard; respect for child assent where appropriate (4.2.1–4.2.12).
• Chapter 4.3: People in dependent or unequal relationships
  • Dependency risks in consent; allow support mechanisms and possibly independent participant advocates; protect against coercion; safeguard confidentiality and relationship dynamics (4.3.1–4.3.10).
• Chapter 4.4: People highly dependent on medical care who may be unable to give consent
  • Includes neonatal, terminal, emergency, and ICU contexts; may approve research if benefits justify risks and capacity considerations are managed; seek consent where possible; otherwise, guardian/authorized representative or exception under specific rules (4.4.1–4.4.14).
• Chapter 4.5: People with cognitive impairment, intellectual disability, or mental illness
  • Respect autonomy where possible; determine capacity with explicit criteria; consent by participant or guardian; reassess capacity over time; ensure support and proper witnessing; respect refusal; guidance for review processes (4.5.1–4.5.11).
• Chapter 4.6: People who may be involved in illegal activities
  • Research may expose illegal activity; discuss consent implications; consider privacy and legal obligations; decision-making regarding disclosing information to authorities; harm minimisation and confidentiality protections (4.6.1–4.6.7).
• Chapter 4.7: Aboriginal and Torres Strait Islander Peoples
  • Emphasises six core values: Reciprocity, Respect, Equality, Responsibility, Survival and Protection, Spirit and Integrity; engagement with communities and stakeholders; local level support for methods; culturally safe engagement; rights to interpretation and data use; community reporting and reporting back to communities (4.7.1–4.7.12).
• Chapter 4.8: People in other countries
  • Overseas research must respect local values and laws; ensure equivalent protections; communicate ethics review processes; manage cross-border review with local partners; address recruitment, consent, and remuneration; ensure non-exploitative distribution of burdens/benefits; provide accessible local contact points (4.8.1–4.8.21).

SECTION 5: RESEARCH GOVERNANCE AND ETHICS REVIEW

• Chapter 5.1: Governance responsibilities of institutions
  • Institutions must have governance frameworks; ethics review must occur prior to commencement; risk-based pathways for ethics review; exemption decisions are the institution’s responsibility; align with National Statement and Code; consider audits and consumer/community perspectives; publish policies (5.1.1–5.1.38).
  • Risk levels guide review pathways; higher than low risk requires HREC; non-HREC pathways must be competent and properly resourced (5.1.10–5.1.14).
  • Provisions for exemptions and retention of records; objective to minimize duplication of ethics review (5.1.15–5.1.18).
  • Public accountability and annual reporting to NHMRC; monitoring and ongoing governance responsibilities (5.1.19–5.1.29).
• Chapter 5.2: Responsibilities of HRECs and other ethics review bodies
  • HRECs must implement standard operating procedures; document meeting procedures; maintain confidentiality; disclose and manage conflicts of interest; decisions must be communicated in writing; external advice and observers may be used under safeguards (5.2.1–5.2.14).
  • Recordkeeping and reporting requirements; retention of full proposal records; decisions and amendments; management of external reviews (5.2.15–5.2.21).
• Chapter 5.3: Responsibilities of researchers
  • Proposals must demonstrate merit and integrity; comply with CPMP/ICH Good Clinical Practice and other professional standards where applicable; present accessible information to participants; disclose funding sources; provide ongoing training and ensure transparency in communications (5.3.1–5.3.9, 5.3.11–5.3.12).
• Chapter 5.4: Monitoring
  • Institutions bear primary monitoring responsibility; monitoring must fit risk, size, and complexity; use of DSMBs or independent monitors; reporting requirements; suspension/withdrawal processes; post-suspension obligations (5.4.1–5.4.19).
• Chapter 5.5: Minimising duplication of ethics review
  • Encourage cross-institutional harmonisation; avoid duplicative reviews; accept external reviews under defined criteria; specify site and jurisdiction details; programmatic acceptance where appropriate (5.5.1–5.5.7).
• Chapter 5.6: Disclosure of interests and management of conflicts of interest
  • Require disclosure of actual or potential conflicts by institutions, review bodies, and researchers; implement management strategies (e.g., recusal, disclosure to participants, independent oversight); maintain records of disclosures (5.6.1–5.6.7).
• Chapter 5.7: Complaints
  • Establish accessible complaints processes; handle complaints promptly; escalate to independent assessors if needed; reference to the Australian Code for the Responsible Conduct of Research (5.7.1–5.7.4).
• Chapter 5.8: Accountability
  • Outlines multi-level accountability across researchers, review bodies, institutions, funders, and regulators; annual reporting to NHMRC; ensure alignment with national standards and proper governance (5.8.1–5.8.4).

TERMS USED IN THIS DOCUMENT (GLOSSARY SUMMARY)

• Key terms with definitions (examples):
  • Cell line: lab-grown cells; may be immortalised or finite.
  • Co-researcher: participant or sub-group contributing significantly to project planning, data collection, analysis, or interpretation.
  • Data vs information: raw data vs interpreted results; identifiability concerns.
  • Deception and covert observation: ethically scrutinised, with controlled allowances via limited disclosure or waivers.
  • Genomic data/research: hereditary implications, familial impact, and possible re-identification risks.
  • Innovation and intervention: new or modified practices; safety and efficacy uncertainties.
  • Opt-out approach: presumption of participation unless declined; not always appropriate for privacy laws.
  • Protocol vs. project description: design and plan documents guiding research.
  • Relatives, index case/proband: family-linked genomic considerations and recruitment dynamics.
  • Findings: primary, secondary, incidental; returnability and counselling requirements.
  • Xenozoonosis: disease transmission risk in xenotransplantation; long-term monitoring.

LA TEX-ENABLED FORMULAS AND CONCEPTS

• Risk concept (definitions across Section 2.1):
  • Risk involves two components:
  • Likelihood of harm or discomfort, and
  • Severity or magnitude of the harm or discomfort, including potential consequences.
  • A succinct representation: $ext{Risk} = ext{Likelihood} imes ext{Magnitude}$ (qualitative translation used in risk profiling).
• Data identifiability spectrum: refer to 3.1.35–3.1.41, which discusses a continuum rather than fixed categories; factors include identifiers, linking keys, and contextual information; strategies include separation of identifiers and content, minimizing variables, and secure data handling.

CONNECTIONS TO FOUNDATIONAL PRINCIPLES AND REAL-WORLD RELEVANCE

• Ethical conduct is grounded in longstanding international codes and human rights instruments; Australian guidelines adapt these to national governance, ensuring legitimacy and public trust.
• The National Statement aligns with the Australian Code for the Responsible Conduct of Research and is designed to work with institutional governance structures, funding, and regulatory bodies to promote responsible, ethically sound research.
• Real-world relevance: the framework supports diverse research types (clinical trials, public health, genomics, biospecimen research, cross-border studies) and emphasizes culturally appropriate practices (e.g., Aboriginal and Torres Strait Islander guidelines).

SUMMARY OF PRACTICAL IMPLICATIONS

• For researchers:
  • Articulate merit, design methods to minimise risk, plan consent processes (including special consent considerations for vulnerable groups and future data use).
  • Prepare data management plans, data sharing policies, and disclosure strategies for findings.
  • Consider family and community implications, especially in genomics and biospecimen research; plan for counselling and follow-up.
• For ethics review bodies (HRECs):
  • Apply proportionate review based on risk; ensure independence, transparency, and appropriate expertise; manage conflicts of interest; maintain robust documentation.
• For institutions:
  • Establish governance frameworks; ensure appropriate monitoring, auditing, reporting, and accountability; resolve duplication of ethics review; ensure resources for long-term monitoring in high-risk areas like xenotransplantation or interventional genomic studies.
• For participants:
  • Receive information in accessible formats; understand their rights (withdrawal, data use, return of results); know how to raise complaints; be aware of potential risks and benefits.

NOTE ON EXAM-READY FOCUS

• Remember the risk-benefit framework and consent principles as the core of ethical review.
• Be able to explain the difference between opt-out and waiver of consent, and when each may be appropriate.
• Understand the specific considerations for biospecimens, genomics, and xenotransplantation, including long-term monitoring and participant counselling.
• Be prepared to discuss how ethical review interacts with governance, regulatory compliance, and public accountability.